PT  - JOURNAL ARTICLE
AU  - Yang, Mei
AU  - Liu, Yuhan
AU  - Zhang, Chunming
AU  - Hsueh, Yi-Ching
AU  - Zhang, Qiangzu
AU  - Fan, Yanhui
AU  - Xu, Juntao
AU  - Huang, Min
AU  - Li, Xu
AU  - Yang, Jianfei
AU  - Tan, Guangming
AU  - Niu, Gang
TI  - A Genome-Informed Functional Modeling Approach to Evaluate the Responses of Breast Cancer Patients to CDK4/6 Inhibitors-Based Therapies and Simulate Real-World Clinical Trials
AID  - 10.1101/2023.05.15.23289976
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.05.15.23289976
4099  - http://medrxiv.org/content/early/2023/07/21/2023.05.15.23289976.short
4100  - http://medrxiv.org/content/early/2023/07/21/2023.05.15.23289976.full
AB  - PURPOSE Varied therapeutic responses were observed among cancer patients receiving the same treatment regimen, highlighting the challenge of identifying patients most likely to benefit from a given therapy. Here, we present an artificial intelligence-based approach, called CDK4/6 inhibitor Response Model (CRM), to address the complexity of predicting patient responses to treatment by a certain clinical scene on CDK4/6 inhibitors (CDK4/6i).PATIENTS AND METHODS To train the CRM, we transformed the genomic data of 980 breast cancer patients from the TCGA database into activity profiles of signaling pathways (APSP) by utilizing the modified Damage Assessment of Genomic Mutations (DAGM) algorithm. A scoring model was then established by random forest algorithm to classify the HR+/HER2− and HR−/HER2− breast cancer molecular subtypes by the differential APSP features between the two, which reasonably reflected the potential role played by CDK4/6 molecules in HR+/HER2− breast cancer cells. The effectiveness of CRM was then tested in a separate local patient cohort (n = 343) in Guangdong, China. Twin in-silico clinical trials (ICT) of previously disclosed clinical trials (NCT02246621, NCT02079636, NCT03155997, NCT02513394, NCT02675231) were performed to demonstrate the potential of CRM in generating concerted results as the real-world clinical outcomes.RESULTS The CRM displayed high precision in classifying HR+/HER2− and HR−/HER2− breast cancer patients in both TCGA (AUC=0.9956) and local patient cohorts (AUC=0.9795). Significantly, the scores were distinct (p = 0.025) between CDK4/6i-treated patients with different responses. Breast cancer patients from different subtypes were grouped into five distinct populations based on the scores assigned by the CRM. From twin ICT, the CRM scores reflected the differential responses of patient groups to CDK4/6i-based therapies.CONCLUSION The CRM score showed not only a robust association to clinically observed CDK4/6i responses but also heterogenetic responses across subtypes. More than half of HR+/HER2+ patients may be benefited from CDK4/6i-based treatment. The CRM empowered us to conduct ICT on different types of cancer patients responding to CDK4/6i-based therapies. These findings showed the potential of CRM as the companioned ICT to guide CDK4/6i application in the clinical end. CRM-guided ICT could be a universal method to demonstrate drug sensitivity to various patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by National Natural Science Foundation of China (grant no. 82072939 to M. Yang), Natural Science Foundation of Guangdong Province (grant no. 2022A1515010425 to M. Yang), Guangzhou Science and Technology Program (grant no. 202206010110 to M. Yang), National Natural Science Foundation of China (grant no. T2125013 to G. Tan), Hefei National Laboratory for Physical Sciences at the Microscale (grant no. KF2020009 to G. Niu).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Guangdong Provincial People's Hospital gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors